Orforglipron Intermediates；Orforglipron Intermediate (S-Isomer); GLP-1 Receptor Agonist Intermediate
CAS:2212022-56-3
Chemical Formula:C26H25F2N7O
Molecular Weight:489.53
Availability: R&D; Commercialization
⬤ CAS No.2212022-56-3
⬤ Packaging type：
20kg barrel；5kg barrel；1kg bag；500g bag ; Customized Packaging
| Product Name | (S)-1-(4-fluoro-2-methyl-2H-indazol-5-yl)-3-(2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3-yl)-1H-imidazol-2(3H)-one |
| CAS No. | 2212022-56-3 |
| Chemical Formula | C26H25F2N7O |
| Molecular Weight | 489.53 |
| Related Categories | Orforglipron Intermediate |
| Boiling Point | 650.0±65.0 °C(Predicted) |
| Density | 1.45±0.1 g/cm3(Predicted) |
| Acidity coefficient (pKa) | 8.39±0.40(Predicted) |
| Storage and Handling | Store in a cool, dry, ventilated place, away from fire and oxidants. |
| Note | This product is exclusively utilized as a synthetic intermediate in pharmaceutical manufacturing and is not intended for direct therapeutic or diagnostic use. |
| Application | Our product is a key intermediate of Orforglipron and is mainly used for: Drug synthesis: Raw materials for the production of GLP-1 receptor agonist drugs for the treatment of type 2 diabetes and obesity. R&D use: As a core structural unit in the development of new metabolic disease drugs. |
Reliable Global Partner
“Tianming Pharmaceutical has redefined reliability for us. Their ability to deliver high-potency APIs and intermediates under tight deadlines—is unmatched. The team’s transparency in documentation and proactive updates make them a stress-free partner. A true backbone for our operations!”
March 18, 2024
Outstanding Technical Guidance
“Few suppliers align so perfectly with EU GMP requirements. Tianming’s commitment to audit-ready quality systems, batch traceability, and purity consistency has streamlined our production processes. Their diligence eliminates regulatory risks—a rare advantage in today’s market.”
February 15, 2024
Beyond Supplier, A Solutions Partner
“Tianming’s technical team doesn’t just deliver materials—they solve problems. When we faced stability challenges with a niche compound, their scientists proposed a tailored purity adjustment that saved our project timeline. Their agility transforms obstacles into opportunities.”
June 15, 2024
Strategic Growth Ally
“Over 5+ years, Tianming has consistently adapted to our evolving needs—whether scaling volumes or supporting custom synthesis projects. Their ethical pricing models and long-term vision make them more than a vendor; they’re integral to our competitive edge.”
April 27, 2024
Comparing Nifedipine & Amlodipine: Onset, duration, and side effects decoded. Demand for amlodipine intermediates? We deliver quality.
Hechi Vice Mayor Chen Zhijie toured Tianming Pharmaceutical’s facilities, praising its R&D strength and the “Jinan R&D + Hechi production” model.
This non-peptide GLP-1 receptor agonist, now in late-stage clinical trials, is redefining possibilities for diabetes and obesity treatment. Let’s unpack what makes it distinctive from both lab bench and manufacturing perspectives.
Leading provider of high-quality APIs and intermediates. Contact us for innovative solutions and expert support.
